Doxycycline anhydrous 40 MG Delayed Release Oral Capsule — RxCUI 901399
RxNorm drug concept · Semantic clinical drug
RxCUI 901399
Semantic clinical drug · SCD
● Current RxNorm concept 11 FDA products
12 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI901399
Official nameDoxycycline anhydrous 40 MG Delayed Release Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped11
Package NDCs mapped12
Reported Medicaid activity (SDUD)2,750 prescriptions · 9 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Doxycycline Injection: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It treats serious bacterial infections, such as Rocky Mountain spotted fever and other tick-borne infections, certain pneumonia-type infections, plague, cholera, and trachoma. It i...
- A healthcare professional gives it as a slow infusion into a vein, usually over one to four hours. It should never go into a muscle or under the skin. Your team will switch you to...
- Nausea, vomiting, diarrhea, and loss of appetite are common. You may also get a rash or burn more easily in the sun, so protect your skin. Irritation of the vein can happen if the...
- What side effects should I expect with Doxycycline Injection?
🕸️ Concept Web — How Doxycycline anhydrous 40 MG Delayed Release Oral... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Doxycycline anhydrous 40 MG Delayed Release Oral Capsule
RxCUI 901399 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Doxycycline
3640IN -
Doxycycline anhydrous
1545992PIN
-
Doxycycline
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Oracea
643822BN
-
Oracea
-
Dose forms 13
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Doxycycline Delayed Release Oral Capsule
378209SCDF -
Doxycycline anhydrous Delayed Release Oral Capsule
2647975SCDFP -
Doxycycline Oral Product
1160778SCDG -
Doxycycline Pill
1160779SCDG -
Doxycycline anhydrous Oral Product
2663160SCDGP -
Doxycycline anhydrous Pill
2661725SCDGP -
Doxycycline Delayed Release Oral Capsule [Oracea]
901400SBDF -
Doxycycline anhydrous Delayed Release Oral Capsule [Oracea]
2656574SBDFP - +5 more in this family
-
Doxycycline Delayed Release Oral Capsule
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Doxycycline anhydrous 40 MG
1653353SCDC -
Doxycycline anhydrous 40 MG Delayed Release Oral Capsule [Oracea]
901401SBD -
Doxycycline anhydrous 40 MG [Oracea]
1653355SBDC
-
Doxycycline anhydrous 40 MG
Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Doxycycline anhydrous 40 MG
SCDC · 1653353 -
Doxycycline Delayed Release Oral Capsule
SCDF · 378209 -
Doxycycline anhydrous Delayed Release Oral Capsule
SCDFP · 2647975 -
Doxycycline Oral Product
SCDG · 1160778 -
Doxycycline Pill
SCDG · 1160779 -
Doxycycline anhydrous Oral Product
SCDGP · 2663160 -
Doxycycline anhydrous Pill
SCDGP · 2661725
Brand-Name Concepts
-
Doxycycline anhydrous 40 MG Delayed Release Oral Capsule [Oracea]
SBD · 901401 -
Doxycycline anhydrous 40 MG [Oracea]
SBDC · 1653355 -
Doxycycline Delayed Release Oral Capsule [Oracea]
SBDF · 901400 -
Doxycycline anhydrous Delayed Release Oral Capsule [Oracea]
SBDFP · 2656574 -
Oracea Oral Product
SBDG · 1182896 -
Oracea Pill
SBDG · 1182897 -
Oracea
BN · 643822
📦 FDA Products & Package NDCs
11 products · 12 package NDCs
12 package NDCs map to RxCUI 901399 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00299-3822-30 | 30 CAPSULE in 1 BOTTLE (0299-3822-30) | ORACEA | Galderma Laboratories, L.P. | 2010-05-14 |
| 11788-0134-30 | 30 CAPSULE in 1 BOTTLE (11788-134-30) | DOXYCYCLINE | AiPing Pharmaceutical, Inc. | 2026-01-16 |
| 33342-0346-07 | 30 CAPSULE in 1 BOTTLE (33342-346-07) | doxycycline | Macleods Pharmaceuticals Limited | 2025-03-27 |
| 33342-0346-12 | 10 BLISTER PACK in 1 CARTON (33342-346-12) / 10 CAPSULE in... | doxycycline | Macleods Pharmaceuticals Limited | 2025-03-27 |
| 43547-0590-03 | 30 CAPSULE in 1 BOTTLE (43547-590-03) | Doxycycline | Solco Healthcare US,LLC | 2025-12-15 |
| 43598-0457-30 | 30 CAPSULE in 1 BOTTLE (43598-457-30) | Doxycycline | Dr.Reddys Laboratories Inc | 2024-04-23 |
| 46708-0785-30 | 30 CAPSULE in 1 BOTTLE (46708-785-30) | DOXYCYCLINE | Alembic Pharmaceuticals Limited | 2024-06-27 |
| 60505-4775-03 | 30 CAPSULE in 1 BOTTLE (60505-4775-3) | Doxycycline | Apotex Corp. | 2024-10-31 |
| 62332-0785-30 | 30 CAPSULE in 1 BOTTLE (62332-785-30) | DOXYCYCLINE | Alembic Pharmaceuticals Inc. | 2024-06-27 |
| 68308-0668-30 | 30 CAPSULE in 1 BOTTLE (68308-668-30) | DOXYCYCLINE | Mayne Pharma Inc. | 2023-02-27 |
| 70748-0308-06 | 30 CAPSULE in 1 BOTTLE (70748-308-06) | DOXYCYCLINE | Lupin Pharmaceuticals, Inc. | 2024-04-08 |
| 73190-0040-30 | 30 CAPSULE in 1 BOTTLE (73190-040-30) | Doxycycline | AvKARE | 2025-09-02 |
Observed labelers:
Macleods Pharmaceuticals Limited (2) ·
AiPing Pharmaceutical, Inc. (1) ·
Alembic Pharmaceuticals Inc. (1) ·
Alembic Pharmaceuticals Limited (1) ·
Apotex Corp. (1) ·
AvKARE (1)
· +5 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
💲 Pricing (NADAC)
NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$5.8492
Range $5.8492–$29.0899
· middle 50% $5.8492–$5.8492
· 8 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.